Polypid Ltd. Stock Price, News & Analysis

PolyPid Ltd. (Nasdaq: PYPD) announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference scheduled for September 29 at 2:00 PM EDT. During the event, Dikla Czaczkes Akselbrad, EVP and CFO, will present corporate highlights and discuss recent developments, particularly focusing on PolyPid's Phase 3 clinical trials for its lead product candidate D-PLEX100, aimed at preventing surgical site infections.

PolyPid specializes in developing targeted therapeutics using its proprietary PLEX technology.

PolyPid Ltd. (Nasdaq: PYPD) announced promising preclinical results for OncoPLEX, a therapy designed for glioblastoma multiform (GBM), demonstrating significant inhibition of tumor growth in two animal models. A single application of OncoPLEX achieved 98% tumor growth inhibition and a 60% survival rate after 41 days, outperforming systemic treatments. The company is preparing for a pre-IND meeting with the U.S. FDA by year-end and aims to initiate a phase 1/2 clinical trial in 2022. The results highlight OncoPLEX's potential to improve patient outcomes in aggressive brain tumors.

PolyPid Ltd. (Nasdaq: PYPD) announced that its Co-Founder and CSO, Dr. Noam Emanuel, will present virtually at the World Association against Infection in Orthopaedics and Trauma Congress on August 28, 2021. The presentation, titled Improved Healing of Gustilo Type IIIA and IIIB Open Long Bone Fractures, focuses on a clinical trial of a biodegradable antibiotic bone graft. This session aims to discuss septic non-union and bone loss management and will be attended by 1,700 members globally.

PolyPid Ltd. (PYPD) announced significant recruitment progress in its Phase 3 SHIELD I trial for D-PLEX100, with over 300 patients enrolled. The FDA indicated that a single Phase 3 study might suffice for D-PLEX100's approval in colorectal surgery. Additionally, PolyPid has chosen brain tumors as the initial target for its OncoPLEX therapy. Financially, R&D expenses rose to $7.4 million in Q2 2021, while net losses decreased to $10.5 million compared to $19.1 million in 2020. The company maintains a cash position of $52.9 million, projected to sustain operations into late 2022.

PolyPid Ltd. (Nasdaq: PYPD), a biopharma company focused on improving surgical outcomes with advanced therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice President and CFO, will present at the Investor Summit Virtual Conference on August 18, 2021, at 9:30 am ET. The event is scheduled from August 17-18, 2021, with opportunities for one-on-one meetings throughout. PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing surgical site infections.

PolyPid Ltd. (Nasdaq: PYPD) announced its second quarter 2021 financial results will be reported before the U.S. markets open on August 11, 2021. The company will hold a conference call at 8:30 AM Eastern Time to discuss these results and operational updates. PolyPid specializes in locally administered therapeutics aimed at improving surgical outcomes, with its lead candidate D-PLEX100 currently in Phase 3 trials to prevent surgical site infections. The company emphasizes its proprietary PLEX technology for effective drug delivery.

PolyPid Ltd. (Nasdaq: PYPD) has appointed renowned colorectal surgeon Dr. Anthony J. Senagore as its Senior Medical Director. Dr. Senagore will lead the development of PolyPid’s medical infrastructure in the U.S. and play a pivotal role in the NDA submission for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs). His extensive experience in surgery and healthcare economics is expected to enhance the company’s mission to improve surgical outcomes. The D-PLEX₁₀₀ candidate is currently in Phase 3 clinical trials.

PolyPid (Nasdaq: PYPD) announced a presentation by CFO Dikla Czaczkes Akselbrad at The Raymond James Human Health Innovation Conference on June 23, 2021, at 9:20 am EDT. The conference aims to highlight innovations in healthcare, with PolyPid focusing on improving surgical outcomes through its proprietary PLEX technology, which enhances drug delivery. The lead candidate, D-PLEX100, is undergoing Phase 3 trials for preventing surgical site infections. The presentation will be available on the company’s Investor Relations site for 90 days following.

PolyPid Ltd. (Nasdaq: PYPD) is a biopharma company focused on enhancing surgical outcomes with controlled, extended-release therapeutics. On June 2, 2021, the company announced its executive team will present at three upcoming healthcare investor conferences: the LD Micro Invitational XI on June 10, the JMP Securities Life Sciences Conference on June 16, and the Raymond James Human Health Innovation Conference on June 21. The Raymond James presentation will be webcast live and available for 90 days on PolyPid's Investor Relations website.